A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

In by Hannah Schaffner

A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

  • Hidden
  • This field is for validation purposes and should be left unchanged.

An Open-Label, Single-Arm, Phase 4 Study to Assess Glycemic Control When Adults With Type 2 Diabetes Switch From a GLP-1 RA to Tirzepatide (SURPASS-SWITCH-2)


Inclusion Criteria
  1. Have Type 2 diabetes (T2D)
  2. Have an HbA1c c ≥6.5% (≥48 mmol/mol) to ≤9.0% (≤75 mmol/mol)
  3. Have a body mass index (BMI) ≥25 kilogram per square meter (kg/m²) at screening
  4. Have been on a stable treatment dose of 1 of the listed GLP-1 RAs for ≥3 months
  5. No treatment with oral antidiabetic medicine (OAM) or on stable doses (for at least 3 months before screening) of up to 3 OAM. The OAM may include metformin, sodium-glucose linked transporter-2 inhibitor (SGLT-2i), thiazolidinediones, or α-glucosidase inhibitors.
Exclusion Criteria
  1. Have Type 1 Diabetes (T1D)
  2. Have a clinical history of
    • proliferative diabetic retinopathy
    • diabetic maculopathy, or
    • nonproliferative diabetic retinopathy that requires acute treatment
  3. Are at high risk for cardiovascular disease or have a history of
    • myocardial infarction
    • percutaneous coronary revascularization procedure
    • carotid stenting or surgical revascularization
    • nontraumatic amputation
    • peripheral vascular procedure
    • cerebrovascular accident
    • or hospitalization for congestive heart failure
  4. Have New York Heart Association (NYHA) Functional Classification Class IV congestive heart failure
  5. Have a history of ketoacidosis or hyperosmolar state or coma
  6. Have a history of severe hypoglycemia or hypoglycemia unawareness within the 6 months.
Back to Current Studies